Qualigen Therapeutics Inc (QLGN)
4.20
+0.02
(+0.56%)
USD |
NASDAQ |
Nov 14, 12:18
Qualigen Therapeutics Enterprise Value: 4.630M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 4.630M |
| November 12, 2024 | 4.448M |
| November 11, 2024 | 4.713M |
| November 08, 2024 | 5.067M |
| November 07, 2024 | 4.890M |
| November 06, 2024 | 5.008M |
| November 05, 2024 | 5.295M |
| November 04, 2024 | 5.262M |
| November 01, 2024 | 5.163M |
| October 31, 2024 | 4.254M |
| October 30, 2024 | 4.372M |
| October 29, 2024 | 4.430M |
| October 28, 2024 | 4.627M |
| October 25, 2024 | 4.882M |
| October 24, 2024 | 4.515M |
| October 23, 2024 | 6.322M |
| October 22, 2024 | 6.398M |
| October 21, 2024 | 6.555M |
| October 18, 2024 | 6.135M |
| October 17, 2024 | 5.943M |
| October 16, 2024 | 5.968M |
| October 15, 2024 | 6.017M |
| October 14, 2024 | 6.168M |
| October 11, 2024 | 6.154M |
| October 10, 2024 | 6.195M |
| Date | Value |
|---|---|
| October 09, 2024 | 5.938M |
| October 08, 2024 | 5.982M |
| October 07, 2024 | 6.198M |
| October 04, 2024 | 6.088M |
| October 03, 2024 | 5.938M |
| October 02, 2024 | 5.971M |
| October 01, 2024 | 6.047M |
| September 30, 2024 | 6.226M |
| September 27, 2024 | 6.226M |
| September 26, 2024 | 6.226M |
| September 25, 2024 | 6.202M |
| September 24, 2024 | 6.150M |
| September 23, 2024 | 6.064M |
| September 20, 2024 | 6.118M |
| September 19, 2024 | 6.350M |
| September 18, 2024 | 6.256M |
| September 17, 2024 | 6.353M |
| September 16, 2024 | 6.164M |
| September 13, 2024 | 5.999M |
| September 12, 2024 | 5.948M |
| September 11, 2024 | 5.739M |
| September 10, 2024 | 5.715M |
| September 09, 2024 | 5.739M |
| September 06, 2024 | 5.869M |
| September 05, 2024 | 3.568M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.607M
Minimum
Dec 29 2023
122.79M
Maximum
Aug 05 2020
23.51M
Average
7.085M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.577M |
| Total Expenses (Quarterly) | 1.741M |
| EPS Diluted (Quarterly) | -10.50 |
| Earnings Yield | -2.08K% |
| Normalized Earnings Yield | -6355.62 |